Mark Lawson - 13 Oct 2026 Form 3 Insider Report for Helus Pharma Inc. (HELP)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
23 Oct 2026, 19:13:03 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mark Lawson
Filing notes and source

Key filing fact

Mark Lawson filed Form 3 for Helus Pharma Inc. (HELP) on 23 Oct 2026.

Key facts

  • This page summarizes Mark Lawson's Form 3 filing for Helus Pharma Inc. (HELP).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 23 Oct 2026, 19:13.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438216 Primary reporting owner

Lawson Mark

Relationship
Director
Address
C/O HELUS PHARMA INC., 100 KING STREET WEST, SUITE 5600, TORONTO, ONTARIO, CANADA
Signature
/s/ Mark Lawson
Signature date
23 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HELP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,026
Date
13 Oct 2026
Ownership
Direct
HELP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
157,000
Date
13 Oct 2026
Ownership
Held by Four Paths Partners Ltd.
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Held by Four Paths Partners Ltd., a corporation owned and controlled by the reporting person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .